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Background
In response to the financial crisis and under the EU/IMF
Programme of Financial Support, Ireland committed to
make savings on pharmaceutical expenditure, including
through a system of generic substitution (GS) and refer-
ence pricing (RP) [1]. This intervention involved GS
based on fifth level ATC code (active substance), which
was followed by RP 3-5 months later. The aim of this
analysis was to determine estimates of savings to the
healthcare payer resulting from the introduction of GS
and RP and to examine utilisation patterns pre and post
intervention.
Methods
This study was a retrospective analysis of patient-level
national pharmacy claims data from January 2013-October
2014 inclusive. These data were sourced from the publicly-
funded Irish community pharmacy drug reimbursement
schemes. For each product deemed interchangeable for
GS, average prices over the prior 6 months were calculated
(‘pre-price’). Pre-prices were then assigned to claims
records for the product over the 6 months following RP.
Actual ingredient cost expenditure and expected expendi-
ture based on pre-prices were compared and total savings
were calculated. Trends in generic versus proprietary pro-
duct uptake were also monitored.
Results
Forty-one product types representing 15 active substances
(fifth level ATC) underwent GS and RP between August
2013 and May 2014, resulting in a minimum of 6 months
follow-up. For the scheme serving the majority of public
patients, GS/RP accounted for an overall combined rela-
tive decrease in ingredient cost expenditure of 53% in the
6 months following implementation, amounting to com-
bined 6-month savings of over EUR 35million (total ingre-
dient cost expenditure on these drugs following GS/RP:
EUR 31m). Greatest savings were observed for the drug
atorvastatin, which incurred a 71% expenditure drop,
while lowest relative savings were observed for the drug
ramipril, which incurred a 24% expenditure drop. Generic
usage rates for the drugs concerned increased on average
by 44% with GS/RP introduction.
Conclusions
The introduction of GS and RP led to substantial savings
which corresponded to pre-policy health service official
estimates. Compliance with policies is high with generic
drug usage targets now exceeded. Success factors included
enactment of supportive legislation in 2013, acceptability
of active-substance based GS and the phased nature of the
policy introduction. On-going work will identify non-com-
pliance with the policies and will aim to elucidate factors
affecting the same. The long-term impact of the policies
has yet to be determined.
* Correspondence: spillasc@tcd.ie
1National Centre for Pharmacoeconomics, St James’s Hospital, Dublin, 8,
Ireland
Full list of author information is available at the end of the article
Spillane et al. Journal of Pharmaceutical Policy and Practice 2015, 8(Suppl 1):O10
http://www.joppp.org/content/8/S1/O10
© 2015 Spillane et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1National Centre for Pharmacoeconomics, St James’s Hospital, Dublin, 8,
Ireland. 2Department of Pharmacology and Therapeutics, School of Medicine,
Trinity College Dublin, Dublin, 2, Ireland.
Published: 5 October 2015
Reference
1. Economic Adjustment Programme for Ireland Autumn 2012 Review




Cite this article as: Spillane et al.: Introduction of generic substitution
and reference pricing in Ireland: early effects on state pharmaceutical
expenditure and generic penetration, and associated success factors.
Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Spillane et al. Journal of Pharmaceutical Policy and Practice 2015, 8(Suppl 1):O10
http://www.joppp.org/content/8/S1/O10
Page 2 of 2
